Literature DB >> 14644999

CD200 is a novel p53-target gene involved in apoptosis-associated immune tolerance.

Michael D Rosenblum1, Edit Olasz, Jeffery E Woodliff, Bryon D Johnson, Marja C Konkol, Kimberly A Gerber, Rimas J Orentas, Gordon Sandford, Robert L Truitt.   

Abstract

During apoptotic cell death, biochemical processes modify self-proteins and create potential autoantigens. To maintain self-tolerance in the face of natural cell turnover, the immune system must prevent or control responses to apoptosis-associated autoantigens or risk autoimmunity. The molecular mechanisms governing this process remain largely unknown. Here, we show that expression of the immunoregulatory protein CD200 increases as murine dendritic cells (DCs) undergo apoptosis. We define CD200 as a p53-target gene and identify both p53- and caspase-dependent pathways that control CD200 expression during apoptosis. CD200 expression on apoptotic DCs diminishes proinflammatory cytokine production in response to self-antigens in vitro and is required for UVB-mediated tolerance to haptenated self-proteins in vivo. Up-regulation of CD200 may represent a novel mechanism, whereby immune reactivity to apoptosis-associated self-antigens is suppressed under steady state conditions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14644999     DOI: 10.1182/blood-2003-09-3184

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

1.  Long term potentiation is impaired in membrane glycoprotein CD200-deficient mice: a role for Toll-like receptor activation.

Authors:  Derek A Costello; Anthony Lyons; Stephanie Denieffe; Tara C Browne; F Fionnuala Cox; Marina A Lynch
Journal:  J Biol Chem       Date:  2011-08-11       Impact factor: 5.157

2.  Endothelial CD200 is heterogeneously distributed, regulated and involved in immune cell-endothelium interactions.

Authors:  Ya-Chen Ko; Hsiung-Fei Chien; Ya-Fen Jiang-Shieh; Chiu-Yun Chang; Man-Hui Pai; Jian-Pei Huang; Hui-Min Chen; Ching-Hsiang Wu
Journal:  J Anat       Date:  2009-01       Impact factor: 2.610

3.  p53-expressing conditionally replicative adenovirus CNHK500-p53 against hepatocellular carcinoma in vitro.

Authors:  Hong-Chuan Zhao; Qi Zhang; Yang Yang; Min-Qiang Lu; Hua Li; Chi Xu; Gui-Hua Chen
Journal:  World J Gastroenterol       Date:  2007-02-07       Impact factor: 5.742

4.  CD200 modulates macrophage cytokine secretion and phagocytosis in response to poly(lactic co-glycolic acid) microparticles and films.

Authors:  E Y Chen; S Chu; L Gov; Y K Kim; M B Lodoen; A J Tenner; W F Liu
Journal:  J Mater Chem B       Date:  2017-01-10       Impact factor: 6.331

5.  Sneaky Entry of IFNγ Through Arsenic-Induced Leaky Blood-Brain Barrier Reduces CD200 Expression by Microglial pro-Inflammatory Cytokine.

Authors:  Vikas Singh; Shaivya Kushwaha; Ruchi Gera; Jamal Ahmad Ansari; Juhi Mishra; Jayant Dewangan; Satyakam Patnaik; Debabrata Ghosh
Journal:  Mol Neurobiol       Date:  2018-06-12       Impact factor: 5.590

Review 6.  Is the CD200/CD200 receptor interaction more than just a myeloid cell inhibitory signal?

Authors:  Konstantinos Minas; Janet Liversidge
Journal:  Crit Rev Immunol       Date:  2006       Impact factor: 2.214

7.  Targeting activation-induced cytidine deaminase overcomes tumor evasion of immunotherapy by CTLs.

Authors:  Jin-Qing Liu; Pramod S Joshi; Chuansong Wang; Hani Y El-Omrani; Yi Xiao; Xiuping Liu; John P Hagan; Chang-Gong Liu; Lai-Chu Wu; Xue-Feng Bai
Journal:  J Immunol       Date:  2010-04-19       Impact factor: 5.422

Review 8.  The Neuro-Immune-Regulators (NIREGs) Promote Tissue Resilience; a Vital Component of the Host's Defense Strategy against Neuroinflammation.

Authors:  Yosra Bedoui; Jim W Neal; Philippe Gasque
Journal:  J Neuroimmune Pharmacol       Date:  2018-06-16       Impact factor: 4.147

Review 9.  Recent advances into the role of pattern recognition receptors in transplantation.

Authors:  Hrishikesh S Kulkarni; Davide Scozzi; Andrew E Gelman
Journal:  Cell Immunol       Date:  2020-03-07       Impact factor: 4.868

10.  Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China.

Authors:  Guangyu Ma; Hideaki Shimada; Kenzo Hiroshima; Yuji Tada; Nobuo Suzuki; Masatoshi Tagawa
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.